Page 176 - 2026 SMOG
P. 176

TRANEXAMIC ACID (CYKLOKAPRON/LYSTEDA)
                              Class/Mechanism of Action
         •  Antifibrinolytic Agent, Hemostatic Agent
           Displaces plasminogen from fibrin, resulting in inhibition of fibrinolysis, and inhibits the proteolytic
           activity of plasmin.
                                    Indications
         •  Off-Label Indications
              ˚  Trauma-associated hemorrhage: casualty likely needing blood transfusion (hemorrhagic shock,
             elevated lactate, one or more major amputations, penetrating torso trauma, or evidence of severe
             bleeding)
              ˚  Postpartum hemorrhage (continued bleeding despite Oxytocin and fundal massage)
              ˚  Post-operative hemorrhage by dissection, enteric staples, or suspected internal bleeding
              ˚  Signs or symptoms of moderate or severe TBI or altered mental status associated with trauma
                                  Contraindications
         •  TXA is contraindicated in trauma if the dose is not given within the first 3 hours following the
           traumatic event (ideal dosing timeframe is as soon as possible)
         •  Hypersensitivity to tranexamic acid or any component of the formulation
         •  Non-traumatic subarachnoid hemorrhage
         •  Thromboembolic disease (Cerebral Thrombosis, DVT, PE)
                            Adverse Reactions/Precautions
         •  Disseminated intravascular coagulation (DIC): Use with extreme caution in patients with DIC
           requiring antifibrinolytic therapy; patients should be under the strict supervision of a physician
           experienced in treating this disorder. TXA should be used in patients with trauma-related DIC
         •  Thrombosis (especially when given after 3 hours from injury)
         •  Seizures have been reported; myoclonus is noted in 20% of patients after administration
         •  Visual defects have been reported: vision color change, impairment, loss, retinal artery, and venous
           occlusion
         •  Pregnancy: Category B
         •  Lactation: Use caution
                                Dose/Administration
                                                    PEDIATRIC
                      ADULT
                                              (Always reference Broselow Tape)
         Trauma-Associated Hemorrhage/Severe TBI   Trauma-Associated Hemorrhage
         (Off-Label use)                 (Off-Label use)
         •  IV/IO                        •  IV/IO
              ˚  Initial: 2g in 100mL NS or LR bolus over     ˚  Loading dose: 15mg/kg over 10min (max
                                             dose: 1g), followed by 2mg/kg/hr for 8hr
             10min, or 2g IV/IO push (given over 10min),
             <3hr from time of injury        (max dose: 1g)
         Suspected Post-Operative Hemorrhage by
         Dissection, Enteric Staples, or Suspected
         Internal Bleeding
         •  IV/IO
              ˚  2g in 100mL NS or LR bolus over 10min,
             or 2g IV/IO push (given over 10min), <3hr
             from time of injury


        168  •   MEDICATIONS
   171   172   173   174   175   176   177   178   179   180   181